GSK plc (NYSE:GSK) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. cut its holdings in GSK plc (NYSE:GSK) by 19.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 20,765 shares of the pharmaceutical company’s stock after selling 5,040 shares during the period. Atria Wealth Solutions Inc.’s holdings in GSK were worth $702,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of GSK. Indiana Trust & Investment Management Co raised its holdings in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 500 shares during the last quarter. Crews Bank & Trust acquired a new position in GSK in the 4th quarter valued at $26,000. ST Germain D J Co. Inc. raised its holdings in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. Finally, Concord Wealth Partners raised its holdings in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Up 3.5 %

Shares of NYSE GSK opened at $38.39 on Wednesday. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.92. The stock has a fifty day moving average price of $34.76 and a 200 day moving average price of $37.30. The company has a market cap of $79.56 billion, a P/E ratio of 24.14, a P/E/G ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.10%. GSK’s dividend payout ratio (DPR) is presently 98.74%.

Analyst Ratings Changes

A number of research firms have recently commented on GSK. Morgan Stanley began coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.